Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

News Conference News AHA 2020

Obesity Worsens Outcomes in COVID-19, Especially for Younger Adults

Shelley Wood

November 18, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

Presentation TCT 2020

TCT 381: Predictors of Ischemic and Bleeding Outcomes in High Bleeding Risk Patients Implanted With the SYNERGY Stent – A Post-Hoc Analysis From the EVOLVE Short DAPT Study

Presenter: Robert Yeh

October 14, 2020

Presentation TCT 2020

TCT 262: Percutaneous Coronary Intervention of Long Coronary Lesions With the Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY 48 mm Stent: Primary Outcomes of the EVOLVE 48 Study

Presenter: Dimitri Karmpaliotis

October 14, 2020

News Daily News

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

Michael O'Riordan

September 18, 2020

News Conference News ESC 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

Caitlin E. Cox

August 31, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

News Conference News ACC 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

Caitlin E. Cox

March 28, 2020

Advertisement

Obesity Worsens Outcomes in COVID-19, Especially for Younger Adults

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

TCT 381: Predictors of Ischemic and Bleeding Outcomes in High Bleeding Risk Patients Implanted With the SYNERGY Stent – A Post-Hoc Analysis From the EVOLVE Short DAPT Study

TCT 262: Percutaneous Coronary Intervention of Long Coronary Lesions With the Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY 48 mm Stent: Primary Outcomes of the EVOLVE 48 Study

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content